BioSpace News Archive

Tryp would like to invite all current shareholders and prospective investors to connect directly with Tryp’s management team to discuss many of the Company’s achievements since its Initial Public Offering in December 2020 and look ahead to additional developments in 2021.

The clinic opened in March and offers a comfortable and convenient location for ScreenPro clients.

MustGrow’s safe and effective natural, organic biofumigant, biopesticide and bioherbicide are plant-based

PTC Therapeutics, Inc. announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular atrophy treated with Evrysdi™ obtained increases in survival and sustained improvements in achieving key motor milestones, including head control, sitting, rolling over, and further developing towards acquiring the ability to stand, and walk.

RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat COVID-19 induced lung injury, announced its 2020 financial results for the year ended December 31, 2020 and provided a business update.

Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announces the granting of a new patent from the United States Patent and Trademark Office for patent application number 16/190,450.

Strong capital base and cash runway extended into the first quarter of 2025, with PureTech level cash and cash equivalents of $443.4 million as of March 31, 20211 ($349.4 million as of December 31, 20202) and consolidated cash and cash equivalents of $486.5 million as of March 31, 20213 ($403.9 million as of December 31, 20204)

SciBase Holding AB [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced the publication of a groundbreaking article presenting the “epithelial barrier hypothesis” in Nature Reviews Immunology.

Seegene Inc., a leading molecular diagnostics firm said its Italian subsidiary, the Arrow Diagnostics Srl, has secured the public procurement worth over EUR 89.3 million, the largest volume of tender in the history of its Italian branch since 2014.

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the Annual Report of the financial year 2020.